Sayana Press

Product Overview

Alternative Name: Depo-subQ + Uniject

Development Status: SRA/WHO PQ Approved

Target: Female

Mode: Hormonal

Delivery Type: Injectable

Duration Type: Long-acting

Description: Sayana Press contains 104 mg of depot medroxyprogesterone acetate (DMPA) per 0.65 mL dose and is administered via subcutaneous (SC) injection using the Uniject™ injection system, a small pre-filled single use device.

Updated date: July 26, 2016

Vertical Tabs

Status

Project Phase: Post-development

Project Stage: Marketed

Status Details:
  • Pfizer registered depo-subQ provera 104™, the same drug in Sayana Press, with the US FDA in 2004. Sayana and Sayana Press are also registered with the UK Medicines and Healthcare Products Regulatory Agency (MHRA). It was approved in the European Union via procedure number UK/H/0960/002UK/H/0960/002.
  • Sayana Press is being introduced into Bangladesh, Burkina Faso, Niger, Senegal, and Uganda in 2014.

Download Product Report